<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619073</url>
  </required_header>
  <id_info>
    <org_study_id>CPFS 2008-1</org_study_id>
    <nct_id>NCT00619073</nct_id>
  </id_info>
  <brief_title>PACT (Platelet Activity After Clopidogrel Termination)</brief_title>
  <acronym>PACT</acronym>
  <official_title>PACT (Platelet Activity After Clopidogrel Termination)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is a medication that is used to decrease the ability of platelets to form blood
      clots.

      The theory has been proposed that, in patients with coronary artery disease or stroke,
      increased platelet function after discontinuation of clopidogrel therapy is associated with
      an increased clotting risk. However, this theory has never been rigorously tested.

      The goal of this research is to determine whether discontinuation of clopidogrel results in
      increased platelet function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will address the question: does discontinuation of clopidogrel result in
      platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover study
      in normal subjects, in whom platelet reactivity will be measured before clopidogrel or
      placebo, during clopidogrel or placebo, and at various time points after discontinuation of
      clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75
      mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of
      study assessment in both the clopidogrel arm and the placebo arm, because the clinically
      relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel
      result in platelet hyperreactivity?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention.</measure>
    <time_frame>Baseline and 45 days after intervention</time_frame>
    <description>Value at 45 days after intervention minus value at baseline in platelet surface activated GPIIb-IIIa complex using flow cytometry.The types and concentrations of agonists used in the flow cytometry assays reported here were: ADP 0.5, 1, and 20 µmol/L; thrombin receptor activating peptide (TRAP) 1 and 20 µmol/L; and a combination of collagen 5 µg/mL and epinephrine 5 µmol/L. Mean Florescence Intensity (MFI) is used as unit of measure. MFI indicates relative degree of shift in fluorescence intensity of a population of platelets in arbitrary units.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Blood Platelets</condition>
  <condition>Clopidogrel</condition>
  <arm_group>
    <arm_group_label>Clopidogrel + aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel + aspirin</intervention_name>
    <description>Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.</description>
    <arm_group_label>Clopidogrel + aspirin</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.</description>
    <arm_group_label>Placebo + aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.</description>
    <arm_group_label>Clopidogrel + aspirin</arm_group_label>
    <arm_group_label>Placebo + aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a normal healthy subject

          -  Must be between 21-70 years old

          -  Must be able to take aspirin and clopidogrel.

          -  Must be able to have blood drawn 16 times over approximately 3 months.

        Exclusion Criteria:

          -  Subject who is currently taking aspirin or another anti-platelet drug such as
             clopidogrel. Subject must be free of these medications for 10 days before enrolling in
             this study.

          -  Subject who is currently taking a non-steroidal anti-inflammatory drug such as
             ibuprofen or naproxen. Subject must be free of these medications for 3 days before
             enrolling in this study.

          -  Subject who is currently taking medications for depression or medications that lower
             blood pressure or lower blood sugar.

          -  Subject who are pregnant or may become pregnant during the study or who is breast
             feeding.

          -  Subject with a known allergy to aspirin or clopidogrel.

          -  Cigarette smoking or use of other nicotine product.

          -  Subject with a history of any of the following: coronary artery disease; stroke;
             bleeding disorder; ongoing bleeding; previous life-threatening hemorrhage; stomach
             ulcers; gastrointestinal bleeding within the past 1 month; major surgery within the
             past 1 month; minor surgery within the past 2 weeks; or platelet transfusion within
             the past 7 days.

          -  Subject with a blood count, measured on the pre-study drug blood sample, that is not
             in the normal range.

          -  Subject who is enrolled in another clinical trial of an investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan D. Michelson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.platelets.org/director.htm</url>
    <description>Home page of the study principal investigator</description>
  </link>
  <results_reference>
    <citation>Frelinger AL 3rd, Barnard MR, Fox ML, Michelson AD. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct;3(5):442-9. doi: 10.1161/CIRCINTERVENTIONS.110.937961. Epub 2010 Aug 24.</citation>
    <PMID>20736449</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <results_first_submitted>January 10, 2012</results_first_submitted>
  <results_first_submitted_qc>October 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2012</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood platelets</keyword>
  <keyword>platelet aggregation inhibitors</keyword>
  <keyword>antiplatelet drugs</keyword>
  <keyword>clopidogrel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited at UMass Medical School in Worcester, MA between April 2008 and May 2009.</recruitment_details>
      <pre_assignment_details>15 healthy participants recruited; 16 screened, 1 excluded (1 did not meet inclusion criteria).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clopidogrel Then Placebo</title>
          <description>The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 45 days. After a 30 day washout from completion of first intervention, the subjects will be crossed over to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e. placebo) will then be discontinued and aspirin continued for another 45 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Clopidogrel</title>
          <description>The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 45 days. After a 30 day washout from completion of first intervention, the subjects will be crossed over to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e. clopidogrel) will then be discontinued and aspirin continued for another 45 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention - 60 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (30 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention - 60 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive clopidogrel + aspirin first and placebo + aspirin first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention.</title>
        <description>Value at 45 days after intervention minus value at baseline in platelet surface activated GPIIb-IIIa complex using flow cytometry.The types and concentrations of agonists used in the flow cytometry assays reported here were: ADP 0.5, 1, and 20 µmol/L; thrombin receptor activating peptide (TRAP) 1 and 20 µmol/L; and a combination of collagen 5 µg/mL and epinephrine 5 µmol/L. Mean Florescence Intensity (MFI) is used as unit of measure. MFI indicates relative degree of shift in fluorescence intensity of a population of platelets in arbitrary units.</description>
        <time_frame>Baseline and 45 days after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel + Aspirin</title>
            <description>The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Aspirin</title>
            <description>The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention.</title>
          <description>Value at 45 days after intervention minus value at baseline in platelet surface activated GPIIb-IIIa complex using flow cytometry.The types and concentrations of agonists used in the flow cytometry assays reported here were: ADP 0.5, 1, and 20 µmol/L; thrombin receptor activating peptide (TRAP) 1 and 20 µmol/L; and a combination of collagen 5 µg/mL and epinephrine 5 µmol/L. Mean Florescence Intensity (MFI) is used as unit of measure. MFI indicates relative degree of shift in fluorescence intensity of a population of platelets in arbitrary units.</description>
          <units>mean fluorescence intensity (MFI)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.2" spread="17.6"/>
                    <measurement group_id="O2" value="126.7" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel + Aspirin</title>
          <description>The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Aspirin</title>
          <description>The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan D. Michelson, M.D.</name_or_title>
      <organization>Children's Hospital Boston</organization>
      <phone>617-919-2116</phone>
      <email>alan.michelson@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

